Therapeutic applications of interleukin-2 /
Saved in:
| Imprint: | New York : M. Dekker, c1993. |
|---|---|
| Description: | xviii, 494 p. : ill. ; 24 cm. |
| Language: | English |
| Series: | Basic and clinical oncology ; 2 Basic and clinical oncology v. 2 |
| Subject: | |
| Format: | Print Book |
| URL for this record: | http://pi.lib.uchicago.edu/1001/cat/bib/1499105 |
MARC
| LEADER | 00000cam a2200000 a 4500 | ||
|---|---|---|---|
| 001 | 1499105 | ||
| 003 | ICU | ||
| 005 | 19970810134000.0 | ||
| 008 | 930920s1993 nyua b 001 0 eng c | ||
| 010 | |a 92048300 | ||
| 020 | |a 0824788095 (alk. paper) | ||
| 035 | |a (ICU)BID17459242 | ||
| 035 | |a (OCoLC)27187090 | ||
| 040 | |a DNLM/DLC |c DLC |d DLC$dOrLoB | ||
| 050 | 1 | 0 | |a RC271.I47 |b T48 1993 |
| 060 | |a QZ 267 T3972 | ||
| 082 | |a 616.99/2061 |2 20 | ||
| 245 | 0 | 0 | |a Therapeutic applications of interleukin-2 / |c edited by Michael B. Atkins, James W. Mier. |
| 260 | |a New York : |b M. Dekker, |c c1993. | ||
| 300 | |a xviii, 494 p. : |b ill. ; |c 24 cm. | ||
| 336 | |a text |b txt |2 rdacontent |0 http://id.loc.gov/vocabulary/contentTypes/txt | ||
| 337 | |a unmediated |b n |2 rdamedia |0 http://id.loc.gov/vocabulary/mediaTypes/n | ||
| 338 | |a volume |b nc |2 rdacarrier |0 http://id.loc.gov/vocabulary/carriers/nc | ||
| 490 | 1 | |a Basic and clinical oncology ; |v 2 | |
| 504 | |a Includes bibliographical references and index. | ||
| 505 | 0 | 0 | |g A. |t Immunologic Effects of IL-2. |g 1. |t IL-2 and Its Receptor: Structure, Function, and Regulation of Expression / |r Thomas R. Malek and Nancy S. Gutgsell. |g 2. |t Properties of IL-2-Activated Lymphocytes / |r Elizabeth Ann Grimm. |g 3. |t Properties of Human Tumor-Infiltrating Lymphocytes / |r Kyogo Itoh and Charles M. Balch. |g 4. |t Preclinical Studies with Interleukin-2 in Tumor-Bearing Animals / |r Bishan S. Charak and Amitabha Mazumder. |g 5. |t Biologic Effects of Interleukin-2 Administration on the Immune System / |r David H. Boldt and Thomas M. Ellis -- |g B. |t Clinical Trials With Interleukin-2: Overview / |r Robert I. Fisher. |g 6. |t High-Dose IL-2 Treatment of Melanoma / |r Joseph A. Sparano and Janice P. Dutcher. |g 7. |t High-Dose IL-2 Treatment of Renal Cell Carcinoma / |r Margaret C. Sunderland and Geoffrey R. Weiss. |g 8. |t Low-Dose IL-2 in Cancer Therapy / |r Vera Malkovska, Jeffrey A. Sosman, Jacquelyn Hank and Paul M. Sondel. |g 9. |t Interleukin-2 in the Treatment of Hematologic Malignancies / |r Mark C. Benyunes and Alexander Fefer. |g 10. |t Interleukin-2 in Malignancies Other than Melanoma and Renal Cell Carcinoma / |r Mario Sznol and Michael J. Hawkins. |g 11. |t Locoregional Administration of IL-2 and/or LAK Cells / |r Walter J. Urba. |g 12. |t Adoptive Immunotherapy with Tumor-Infiltrating Lymphocytes / |r Richard Kradin. |g 13. |t Interleukin-2 in Combination with Other Biologic Agents / |r Mario Sznol, Anne Thurn and Frederick R. Aronson. |g 14. |t Interleukin-2 and Chemotherapy / |r Lawrence E. Flaherty and Michael B. Atkins. |g 15. |t Clinical Studies in Europe / |r Gerrit Stoter, A. M. M. Eggermont and R. L. H. Bolhuis. |g 16. |t EuroCetus-Coordinated Clinical Trials / |r Christopher R. Franks, E. M. Loriaux and P. A. Palmer -- |g C. |t Toxicity of Interleukin-2 Immunotherapy: Overview / |r James W. Mier. |g 17. |t The Clinical Toxicities of High-Dose Interleukin-2 / |r Kim Margolin. |g 18. |t Pathogenesis of the Interleukin-2-Induced Vascular Leak Syndrome / |r James W. Mier. |g 19. |t Hemodynamic and Cardiovascular Effects of Interleukin-2 / |r Ellen R. Gaynor and Richard I. Fisher. |g 20. |t Autoimmune Disorders Induced by Interleukin-2 Therapy / |r Michael B. Atkins. |g 21. |t Infectious Complications Associated with Interleukin-2 / |r Mark S. Klempner and David R. Snydman. |g 22. |t Nursing Management of Patients Receiving High-Dose IL-2 Therapy / |r Jody Gould Tsevat, Kerry Kappler and Rhonda Martin -- |g D. |t Interleukin-2 Therapy: Future Directions. |g 23. |t Enhancement of the Antineoplastic Activity of Interleukin-2 / |r David R. Parkinson. |g 24. |t Abrogation of Interleukin-2 Toxicity / |r James W. Mier. |
| 650 | 0 | |a Interleukin-2 |x Therapeutic use. | |
| 650 | 0 | |a Cancer |x Immunotherapy |0 http://id.loc.gov/authorities/subjects/sh87002642 | |
| 650 | 2 | |a Interleukin-2 |x therapeutic use | |
| 650 | 2 | |a Neoplasms |x drug therapy | |
| 650 | 7 | |a Cancer |x Immunotherapy. |2 fast |0 http://id.worldcat.org/fast/fst00845386 | |
| 650 | 7 | |a Interleukin-2 |x Therapeutic use. |2 fast |0 http://id.worldcat.org/fast/fst00976423 | |
| 700 | 1 | 0 | |a Atkins, Michael B., |d 1954- |0 http://id.loc.gov/authorities/names/n92806114 |1 http://viaf.org/viaf/6599173 |
| 700 | 1 | 0 | |a Mier, James W., |d 1947- |0 http://id.loc.gov/authorities/names/n92806115 |1 http://viaf.org/viaf/9049287 |
| 740 | 0 | 1 | |a Therapeutic applications of interleukin-two. |
| 830 | 0 | |a Basic and clinical oncology |v v. 2 |0 http://id.loc.gov/authorities/names/n88525414 | |
| 850 | |a ICU | ||
| 901 | |a ToCBNA | ||
| 903 | |a HeVa | ||
| 929 | |a cat | ||
| 999 | f | f | |i 0891c3cc-f7f3-59a5-a70f-3fbd9eb6881a |s 7ebf4926-d623-5e78-81be-363fb50380fe |
| 928 | |t Library of Congress classification |a RC271.I47T480 1993 |l ASR |c ASR-SciASR |i 2232746 | ||
| 927 | |t Library of Congress classification |a RC271.I47T480 1993 |l ASR |c ASR-SciASR |e CRERAR |b 37578719 |i 2891134 | ||
